Resources Repository
-
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Health/Medicine | Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law | Europe -
ReportPublication 2016Cost-Effectiveness of Mental, Neurological, and Substance Use Disorders
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of …
This report chapter reviews the available cost-effectiveness evidence for the different levels and underpinning strategies of the mental health care system, with a focus on information generated in or for lower and middle income countries. First, the chapter reviews the economic evidence for mental health prevention and protection at the population and community levels of the health and welfare system, including legislative, regulatory, and informational measures at the public policy level (population platform), as well as…
Health/Medicine | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Global -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Health Outcomes | Health/Medicine | Costing Methods | Evidence Synthesis | Health Systems | Economics/Finance | Science/Technology | Europe -
ReportPublication 2015Chapter 4: Cervical Cancer
This chapter focuses on the possibility of primary prevention of cervical cancer as a result …
This chapter focuses on the possibility of primary prevention of cervical cancer as a result of the introduction of two commercially available vaccines against human papillomavirus (HPV). Few low- and middle-income countries (LMICs) have initiated or sustained cytology-based cervical cancer prevention programs, and these countries experience very high incidence and mortality rates. Fortunately, alternative strategies to prevent cervical cancer have been investigated and extensively evaluated in these settings. The authors report findings from cost-effectiveness analyses…
Health/Medicine | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Clinical Care | Science/Technology | Global -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Health Outcomes | Health/Medicine | Costing Methods | Evidence Synthesis | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Science/Technology | North America -
ReportPublication 2012Mortality Risks in Environment, Health and Transport
This report presents a major meta-analysis of value of a statistical life (VSL) estimates derived …
This report presents a major meta-analysis of value of a statistical life (VSL) estimates derived from surveys around the world. The analysis seeks to explain the differences in the estimates, for example across countries. Differences in incomes and the magnitude of the risk reduction were found to be the factors having the strongest impact, but numerous other policy-relevant factors are also important. The report also presents advice on how VSL estimates can be best used…
Climate/Environment | Preferences/Values | Benefit-Cost Analysis | Policy/Regulation | College | Graduate | Critical Thinking/Analysis -
ReportPublication 2003ISPOR Task Force Report: Good Practice for Decision Analytic Modeling in Health-Care
This report describes the consensus of a task force convened to provide modelers with guidelines …
This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies. While published more than a decade ago, it remains a clearly written resource for thinking about how to accurately describe the components of models and their quality. Criteria for assessing the quality of models fell into three areas: model structure, data used as inputs to models, and model validation. Several major themes cut across…
Calibration/Validation | Health/Medicine | Mathematical Models | Science/Technology | Global